Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertrand Routy

Showing results (1-10 of 126) with videos related to

Pageof 13
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 23, 2026
A "healthy gut state" as the key determinant of immune checkpoint inhibitor efficacyHarry Sokol, Arielle Elkrief, Bertrand Routy
Seminars in Nuclear Medicine|May 31, 2022
FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer PatientsMarc-André Léger, Bertrand Routy, Daniel Juneau
Cell|April 9, 2016
Microbiome and Anticancer ImmunosurveillanceLaurence Zitvogel, Maha Ayyoub, Bertrand Routy, et al.
Oncoimmunology|June 7, 2018
The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1Lisa Derosa, Bertrand Routy, Guido Kroemer, et al.
Current Oncology (Toronto, Ont.)|November 24, 2023
The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung CancerSreya Duttagupta, Taiki Hakozaki, Bertrand Routy, et al.
Seminars in Immunology|April 1, 2023
Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncologyRahima Jamal, Meriem Messaoudene, Marina de Figuieredo, et al.
Cancers|August 30, 2020
Tumor Infiltrating Lymphocytes Signature as a New Pan-Cancer Predictive Biomarker of Anti PD-1/PD-L1 EfficacyElise Ballot, Sylvain Ladoire, Bertrand Routy, et al.
Oncoimmunology|May 4, 2016
Prime time for immune-checkpoint targeted therapy at ASCO 2015Aurélien Marabelle, Bertrand Routy, Judith Michels, et al.
ESMO Open|May 12, 2020
New pathways in immune stimulation: targeting OX40Carolina Alves Costa Silva, Francesco Facchinetti, Bertrand Routy, et al.
Nature Reviews. Clinical Oncology|April 1, 2016
Immunological off-target effects of imatinibLaurence Zitvogel, Sylvie Rusakiewicz, Bertrand Routy, et al.
Pageof 13

Showing results (1-10 of 126) with videos related to

Sort By:
Pageof 13
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 23, 2026
A "healthy gut state" as the key determinant of immune checkpoint inhibitor efficacyHarry Sokol, Arielle Elkrief, Bertrand Routy
Seminars in Nuclear Medicine|May 31, 2022
FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer PatientsMarc-André Léger, Bertrand Routy, Daniel Juneau
Cell|April 9, 2016
Microbiome and Anticancer ImmunosurveillanceLaurence Zitvogel, Maha Ayyoub, Bertrand Routy, et al.
Oncoimmunology|June 7, 2018
The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1Lisa Derosa, Bertrand Routy, Guido Kroemer, et al.
Current Oncology (Toronto, Ont.)|November 24, 2023
The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung CancerSreya Duttagupta, Taiki Hakozaki, Bertrand Routy, et al.
Seminars in Immunology|April 1, 2023
Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncologyRahima Jamal, Meriem Messaoudene, Marina de Figuieredo, et al.
Cancers|August 30, 2020
Tumor Infiltrating Lymphocytes Signature as a New Pan-Cancer Predictive Biomarker of Anti PD-1/PD-L1 EfficacyElise Ballot, Sylvain Ladoire, Bertrand Routy, et al.
Oncoimmunology|May 4, 2016
Prime time for immune-checkpoint targeted therapy at ASCO 2015Aurélien Marabelle, Bertrand Routy, Judith Michels, et al.
ESMO Open|May 12, 2020
New pathways in immune stimulation: targeting OX40Carolina Alves Costa Silva, Francesco Facchinetti, Bertrand Routy, et al.
Nature Reviews. Clinical Oncology|April 1, 2016
Immunological off-target effects of imatinibLaurence Zitvogel, Sylvie Rusakiewicz, Bertrand Routy, et al.
Pageof 13